Full-Time
Administrative Assistant II
Education
Confirmed live in the last 24 hours
The Jackson Laboratory
1,001-5,000 employees
Biomedical research using laboratory mice
Compensation Overview
$21.60 - $28.09Hourly
Junior, Mid
Bangor, ME, USA
You match the following The Jackson Laboratory's candidate preferences
Employers are more likely to interview you if you match these preferences:
- High School Diploma
- 2+ years of experience
- Communication skills
- Organization skills
- Interpersonal skills
- Computer skills
- Answers and transfers phone calls
- Manage schedules, arrange appointments and itineraries
- Coordinate meetings, travel, conference calls, and complete expense reports
- Create and edit documents, spreadsheets and presentations
- Prepare reports, meeting minutes and correspondence.
- High School Diploma or GED preferred
- 2 years of experience preferred
The Jackson Laboratory focuses on biomedical research using laboratory mice to explore the genetic and genomic factors behind human diseases. It operates a comprehensive database called the Mouse Genome Informatics (MGI) resource, which provides essential genetic, genomic, and biological data to researchers globally. This database is a key tool for those studying health and disease, setting JAX apart from competitors. As a nonprofit, JAX generates revenue through grants, donations, and the sale of specialized services, including genetically engineered mice and genomic data analysis. The organization has multiple research centers dedicated to studying diseases such as cancer and diabetes, and it also emphasizes education by offering various training programs in bioinformatics and clinical genetics. The goal of The Jackson Laboratory is to advance human health through innovative research and education.
Company Size
1,001-5,000
Company Stage
Grant
Total Funding
$115.8M
Headquarters
Bar Harbor, Maine
Founded
1929
Simplify's Take
What believers are saying
- JAX's partnership with LG AI Research enhances AI-driven genetic research capabilities.
- Expansion in Bar Harbor will increase research capacity and create 95 new jobs.
- Growing demand for rare disease research boosts JAX's unique genetic model offerings.
What critics are saying
- Increased competition in AI-driven research could challenge JAX's market position.
- Facility expansion may strain financial resources and operational management.
- New leadership may shift strategic priorities, affecting existing research directions.
What makes The Jackson Laboratory unique
- JAX's Mouse Genome Informatics resource is a unique, comprehensive genetic database.
- JAX offers specialized genetically engineered mice crucial for advanced biomedical research.
- JAX's educational initiatives cultivate future scientists and healthcare professionals.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Professional Development Budget
Company News
The Jackson Laboratory is preparing to construct a $24 million addition on its main building in Bar Harbor and expects to hire 95 more people to work in the new space.
Bar Harbor, Maine, United States, September 2024 - John O'Reilly has been named Associate Director Talent Acquisition at The Jackson Laboratory.
BAR HARBOR, Maine and MOUNTAIN VIEW, Calif., May 10, 2024 /PRNewswire/ -- The Jackson Laboratory (JAX), an independent, nonprofit biomedical research organization, and AbTherx, an innovator in biotechnology, announced a strategic partnership to develop and commercialize cutting-edge tools to expedite antibody discovery and derisk the development of vital new therapies. This collaboration will include co-development activities and leverages JAX's extensive experience in model research and AbTherx's Atlas™ Mouse platform to address critical challenges facing drug developers of all sizes.The Atlas™ Mouse technologies are engineered to leverage in vivo antibody selection and maturation processes for the creation of human antibodies and are specifically designed to overcome the limitations of historical antibody discovery technologies by offering enhanced speed, diversity, developability, and affinity. Such traits are essential for developing viable lead candidates more swiftly than traditional methods currently allow.JAX will also become the exclusive distributor of select Atlas™ Mouse models, including AbTherx's Full Human Diversity Mouse for monoclonal antibody development as well as the Binary Fixed Light Chain Mouse for bispecific and multispecific antibody development. JAX and AbTherx are additionally exploring opportunities to develop and distribute future models to expand on this existing suite of innovative tools."By combining JAX's expertise in high-quality mouse models with the innovative capabilities of our Atlas™ Mouse platform, we are setting new industry standards," said Justin Mika, CEO of AbTherx. "This collaboration not only enhances our ability to create additional impactful technologies but also ensures that these advancements are within reach of researchers and developers globally, fostering a new era of medical innovation.""Providing access to high-quality research tools is paramount at The Jackson Laboratory, and we are thrilled to extend our capabilities with innovative models that are pivotal for the creation of new therapeutics," said Mitchell Kennedy, Executive Vice President of The Jackson Laboratory and President of JAX Mice, Clinical & Research Services. "Our partnership with AbTherx is a natural synergy, combining our decades of expertise in mouse model development with their deep knowledge in antibody discovery
Dickinson's research background coupled with her successful executive leadership at one of the largest, most complex medical schools will help drive major initiatives and research priorities at a time of rapid growthBAR HARBOR, Maine, May 10, 2024 /PRNewswire/ -- Mary Dickinson, Ph.D., an internationally recognized geneticist, developmental biologist and bioengineer who has pioneered the understanding of human disease through advanced imaging technology, has joined The Jackson Laboratory (JAX) as the inaugural executive vice president and chief scientific officer. Dickinson will lead JAX's research enterprise, overseeing scientific strategy and operations to build on JAX's unique strengths in genetics and genomics."I'm exceedingly confident that Mary's broad leadership experience supporting basic science, translational research, innovation and commercialization at a premier medical school will help take JAX to new heights," said JAX president and CEO Lon Cardon, Ph.D., FMedSci. "With this critical appointment of our chief scientific officer, our team is well-poised to lead major advances on our strategic plan and research priorities in 2024 and beyond."Dickinson's connection with JAX runs deep, rooted in her lifelong immersion in the genetics community and her longstanding history of collaboration with JAX faculty and researchers. With extensive, highly recognized research using mice to study cardiovascular disease, particularly congenital birth defects, Dickinson has a profound appreciation of the JAX mission to improve human health and is an enduring champion of rare disease research."JAX has long been known as a world leader in research innovation, genetic mechanisms and models for disease," said Dickinson. "JAX is far and away distinct from so many institutions in this space, but at the same time integrated within the biomedical community in a way that's really unique for an organization, bridging these communities and advancing precise genomic solutions for disease treatments and cures worldwide."With a global outlook, Dickinson recognizes the powerful role JAX plays in empowering the biomedical community to accelerate discovery for diseases such as Alzheimer's disease, cancer, autoimmune diseases, and addiction. "JAX wants to help people make a difference for as many people as possible, from those in rural Maine to Tokyo," said Dickinson
"The acquisition of CKB is a significant step in Genomenon's mission to curate the entire human genome," shared Mike Klein, CEO of Genomenon